Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12279575 | 0.90 | TRPM8 (0.53) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL478316 | 0.90 | SYK (0.54) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL738204 | 0.90 | SYK (0.54) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL17809612 | 0.87 | SYK (0.53) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL7333862 | 0.87 | CTRB1 (0.55) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL15889351 | 0.87 | SYK (0.52) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL12493693 | 0.87 | CTRB1 (0.55) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL25272324 | 0.86 | SYK (0.54) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL8413738 | 0.86 | SYK (0.54) | SYKCTRB1ATMCTSLCTSS | |
| SCHEMBL7307186 | 0.86 | CTSS (0.53) | SYKCTRB1ATMCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| EP-0233607-B1 | [(2,2,2-Trichloroethoxy) methoxy]amine | E.R. Squibb & Sons, Inc. (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0233607-A2 | [(2,2,2-Trichloroethoxy) methoxy]amine | E.R. Squibb & Sons, Inc. (US) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | SLC14A1, LPXN, UBXN1 | SYK 4634/4885CTRB1 986/4885ATM 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.